Philip Morris International Announces Yearlong Exploration of Inclusion—Furthering the Company’s Commitment to Equality
On International Women’s Day, Philip Morris International Inc. (PMI) (NYSE: PM) announced the launch of a yearlong research and convening initiative entitled “Inclusive Future.” Following a year when inclusion and diversity efforts moved center stage amid the global pandemic, the absence of a single authoritative approach to effectively measure inclusion in business has become even more apparent. To address this need, PMI’s Inclusive Future initiative will explore best practices and established thought leadership to advance the discourse surrounding inclusivity and devise effective and timely ways to promote inclusive cultures. PMI recognizes workplace inclusion and diversity as vital to creativity and innovation—both essential drivers of the company’s business transformation as it works to achieve its vision of a smoke-free future and contribute to a fairer, more equitable world.
“Measuring diversity is the easy part. Measuring and understanding inclusivity is far more complex, as we discovered through trialing inclusivity measurement efforts at PMI,” commented Silke Muenster, Chief Diversity Officer at PMI. “While established frameworks, language, and tools exist for measuring inclusivity today, it is clear that they are far from adequate. In the context of a world that shifted radically in 2020, this new initiative will help us to develop compelling ways to further inclusion within the PMI global organization and, we hope, beyond our walls as well.”
The Inclusive Future work will unfold in phases over the next 12 months, starting with a quantitative and qualitative exploration of the state of inclusion today. This facet of the study will feature a yearlong research partnership with the Institute for Management Development (IMD) in Lausanne, Switzerland, to study how inclusion currently is measured and how this should evolve to drive impact. This will culminate in the publication of the Inclusive Future study results in March 2022.
“Our key objective is to reshape the conversation of inclusion,” said Josefine van Zanten, Chief Equity, Inclusion & Diversity Officer, IMD. “Is today’s measure of inclusion still appropriate in light of the profound socioeconomic evolution of the past year? And how will this evolution impact inclusive leadership and the meaning of inclusion going forward? We are looking to tackle this important and yet complicated part of the equity, inclusion, and diversity equation.”
Beyond the academic research, the Inclusive Future initiative will incorporate engagement activities, exploring and advancing the latest content and thinking on inclusion. These activities will range from hosting digital panels, roundtables, and interviews to celebrating those who are progressing the work today.
As part of the initiative launch, Chief Diversity Officer Silke Muenster will participate in a virtual event on International Women’s Day (March 8) hosted by flagship SHE media site, BlogHer, alongside other female change makers dedicated to advancing economic empowerment for women everywhere. She will also speak on a high-level panel at The Gender Summit on Wednesday, March 10. Hosted by Equality Leaders, the global digital community focused on connecting people, ideas, and organizations to shape the future of equality, diversity, and inclusion, Muenster will join the Gender Summit’s “Lessons from the Top” panel.
To learn more about PMI’s Inclusive Future work and how it is helping to accelerate the company’s business transformation, please visit https://www.pmi.com/inclusion-diversity.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of December 31, 2020, IQOS is available for sale in 64 markets in key cities or nationwide, and PMI estimates that approximately 12.7 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.
Institute for Management Development: Challenging What is and Inspiring What Could Be
The Institute for Management Development (IMD) is an independent academic institution with Swiss roots and global reach, founded 75 years ago by business leaders for business leaders. Since its creation, IMD has been a pioneering force in developing leaders who transform organizations and contribute to society.
Based in Lausanne (Switzerland) and Singapore, IMD has been ranked in the Top 3 of the annual FT’s Executive Education Global Ranking for the last nine consecutive years and in the top five for 17 consecutive years. Our MBA and EMBA programs have repeatedly been singled out among the best in Europe and the world. We believe that this consistency at the forefront of our industry is grounded in IMD’s unique approach to creating “Real Learning. Real Impact”. Led by an expert and diverse faculty, we strive to be the trusted learning partner of choice for ambitious individuals and organizations worldwide. For more information, please visit www.imd.org #IMDImpact
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005179/en/
Contact information
Philip Morris International
David Fraser
T. +41 (0)79 843 8603
E. david.fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 16:00:00 EET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Sciences.
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 15:31:00 EET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 15:00:00 EET | Press release
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Phase II clinical trial in patients with non-infectious anterior uveitis (NIAU). Anterior uveitis is an inflammation of the inner eye including the iris and ciliary body, that typically causes a red, painful, light‑sensitive eye and can lead to vision loss if not treated promptly. NIAU represents 67-90% of uveitis cases in the developed world.1 To treat uveitis a drug must reach the uveal tract inside the eye. Current treatment choices are limited to corticosteroid eye drops and, if insuffic
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 15:00:00 EET | Press release
Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise environments that demand both performance and trust. “Lucend’s Transparent AI platform analyzes billions of data points daily and provides prescriptive recommendations that
IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth26.1.2026 11:15:00 EET | Press release
IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/ From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO) Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO. As part of the transition, Mikko Välimäki steps down from his commercial role following a successful tenure as Co-CEO. He will continue to support the company as an advisor until 31 March 2026 to ensure continuity and a smooth transition. “Our dual CEO approach has served IQM well over the past two years, and I want to thank Mikko Välimäki for his significan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
